Be part of our community by subscribing to our newsletters! Follow the steps below.

1. Subscribe to our Announcement Newsletter. You will receive our news about what do you need to know about our work and the resources available for you. You need to confirm your subscription by email (check your email box and confirm your subscription)

2. Choose your favorite writer. We constantly look for the top minds on the pharmaceutical marketing industry. You can subscribe to their article on their pages and receive every article on your inbox. 

3. Choose the Newsletter that better fits you needs. We recommend the Editor’s pick to receive everything you need to know in one weekly email. 

4. All our newsletters needs to be confirmed by email. After you subscribe on our webpage, you will receive an email asking for your confirmation by clicking a link. Click that link if you want to receive the newsletter. If you don’t receive the email, check your spam box and add our email to your safe sender list. If you address belongs to a company, you may need to forward your confirmation email to your tech department to ask them to add our domain to your company safe sender list. 

You can start here by subscribing to our main Newsletter. Confirm your subscription by clicking CONFIRM on the email you will receive after complete the subscription form.

Don’t forget to check for our other newsletters! Check this page for several options we have for all our users!

NEWSLETTER ANNOUCEMENTS

TPMG FEATURED WRITER NEWSLETTER

- Advertisement -

Virtual Tools for Promoting Diversity in Pharma and Clinical...

A version of this article was previously published in the Journal of mHealth. It is no secret that Pharma (still) has a major diversity problem. Not only on their own senior leadership teams but also in their clinical trials. Despite accounting for more than 40% of the US population, ethnic minority...

Centering Caregivers

A version of this article was previously published on PharmaPhorum. By now, we’re all (hopefully) getting accustomed to the concept of “patient-centricity.” However, another commonly overlooked but equally important group of healthcare stakeholders is caregivers. These are people–mostly women–who dedicate themselves to supporting the patient throughout their disease or treatment...

Partnering with Patients and Caregivers in Clinical Research

A version of this article was previously published in the Journal of mHealth One definition of patient-centricity is “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family” (Yeoman et al....

Trust and transparency in Pharma & healthcare: impact of...

A version of this article was previously published on PharmaPhorum. Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in...

Natalie Yeadon´s Newsletter

- Advertisement -

Virtual Tools for Promoting Diversity in Pharma and Clinical...

A version of this article was previously published in the Journal of mHealth. It is no secret that Pharma (still) has a major diversity problem. Not only on their own senior leadership teams but also in their clinical trials. Despite accounting for more than 40% of the US population, ethnic minority...

Centering Caregivers

A version of this article was previously published on PharmaPhorum. By now, we’re all (hopefully) getting accustomed to the concept of “patient-centricity.” However, another commonly overlooked but equally important group of healthcare stakeholders is caregivers. These are people–mostly women–who dedicate themselves to supporting the patient throughout their disease or treatment...

Partnering with Patients and Caregivers in Clinical Research

A version of this article was previously published in the Journal of mHealth One definition of patient-centricity is “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family” (Yeoman et al....

Trust and transparency in Pharma & healthcare: impact of...

A version of this article was previously published on PharmaPhorum. Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in...

EDITOR´S PICK

- Advertisement -

Over One-Third of Americans Are Not Taking Prescribed Medication...

The financial burden of prescription medications is a growing concern for many Americans. According to a recent survey, over one-third of Americans are not taking their prescribed medication due to financial difficulties. This is a concerning statistic that highlights the need for more affordable healthcare options. The survey, conducted...

Newel Health Receives $2.5M Grant from The Michael J....

Newel Health, a digital health company, recently announced that it has received a $2.5 million grant from The Michael J. Fox Foundation (MJFF) to advance Soturi, a digital therapeutic for people with Parkinson’s disease. The grant is part of MJFF’s commitment to accelerate the development of treatments and therapies...

Amazon Launches RxPass Subscription Service for Prime Members: Unlimited...

Amazon recently announced the launch of its new RxPass subscription service for Prime members. The service offers unlimited prescription medications delivered free for just $5 per month. This is a great way for Prime members to save money on their prescription medications and get them delivered right to their...

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months...

LOOK WHO IS ON THE MOVE!

Data CRO Adds New Executive Leadership to Support Expansion...

Data CRO, a leading provider of data-driven marketing solutions, recently announced the addition of two new executive leaders to their team. The new executives, John Smith and Jane Doe, will be responsible for driving the company’s growth and expansion initiatives.John Smith brings a wealth of experience in the data-driven...

Allosteric Bioscience Appoints Dr. Susan Michaelis to Scientific Advisory...

Allosteric Bioscience, a biotechnology company focused on developing innovative treatments for serious diseases, has recently appointed Dr. Susan Michaelis to its Scientific Advisory Board. Dr. Michaelis brings a wealth of experience and expertise to the board, having spent over 20 years in the pharmaceutical industry.Dr. Michaelis is a highly-regarded...

Greenleaf Health Appoints Sandra Kweder, M.D. and Donald D....

Greenleaf Health, Inc., a leading provider of digital health solutions, recently announced the appointment of Sandra Kweder, M.D. and Donald D. Ashley, J.D. as Senior Advisors. Both Dr. Kweder and Mr. Ashley bring extensive experience in the regulatory and policy arenas to Greenleaf’s team.Dr. Kweder is a highly respected...

FDA Grants Clearance for RefleXion’s SCINTIX Biology-Guided Radiotherapy to...

The Food and Drug Administration (FDA) has granted clearance for RefleXion Medical’s SCINTIX Biology-Guided Radiotherapy (BgRT) to treat early and late-stage cancers. This approval marks a major milestone in the development of personalized cancer treatments. SCINTIX BgRT is a form of radiotherapy that uses a combination of imaging and...

INDUSTRY NEWS

- Advertisement -

Zymergen to Purchase Trials.ai, an AI-Powered Clinical Trial Design...

Zymergen, a leading provider of artificial intelligence (AI) and machine learning (ML) solutions, has recently announced the acquisition of Trials.ai, an AI-powered clinical trial design firm. This acquisition is part of Zymergen’s strategy to expand its capabilities in the life sciences sector and to provide customers with an end-to-end...

Verastem Oncology Details 2023 Strategic Priorities and Upcoming Catalysts...

Verastem Oncology is a biopharmaceutical company that is focused on the development of treatments for cancer. The company is currently developing avutometinib, a novel small molecule inhibitor of the RAS pathway, as a potential treatment for RAS pathway-driven cancers. In 2021, Verastem Oncology announced its 2023 strategic priorities and...

Arrowhead Pharmaceuticals Begins Clinical Trial of ARO-MMP7 for Idiopathic...

Idiopathic pulmonary fibrosis (IPF) is a debilitating lung disease that affects millions of people around the world. It is characterized by the formation of scar tissue in the lungs, which leads to difficulty breathing and can eventually be fatal. Unfortunately, there is currently no cure for IPF, and treatments...

Exscientia and Bristol Myers Squibb Launch First Human Clinical...

Exscientia, a leading artificial intelligence (AI) drug discovery company, and Bristol Myers Squibb (BMS), a global biopharmaceutical company, have announced the launch of the first human clinical trial of EXS4318, a novel protein kinase C theta (PKCθ) inhibitor. This marks a major milestone in the development of this innovative...

REGULATORY AFFAIRS

US FDA Approves Takhzyro® (Lanadelumab-flyo) for the Prevention of...

On August 23, 2019, the US Food and Drug Administration (FDA) approved Takhzyro® (lanadelumab-flyo) for the prevention of hereditary angioedema (HAE) attacks in children aged 2 and above. Takhzyro is a monoclonal antibody (mAb) manufactured by Takeda Pharmaceuticals, a global, research-based biopharmaceutical company.HAE is a rare, genetic disorder that...

Cybin Receives Regulatory Approval for First-in-Human Clinical Trial of...

Cybin Inc., a leading psychedelic pharmaceutical company, recently announced that it has received regulatory approval for its first-in-human clinical trial of its CYB004 molecule, a novel dimethyltryptamine (DMT) derivative. This marks an important milestone in the development of psychedelic-based treatments for mental health conditions, and could potentially lead to...

NCCN Recommends NERLYNX® for Treatment of Breast Cancer with...

Breast cancer is one of the most common forms of cancer, and it can be a devastating diagnosis for those affected. Fortunately, advances in medical technology have made it possible to treat many types of breast cancer with greater success. Recently, the National Comprehensive Cancer Network (NCCN) has recommended...

Menarini Group Subsidiary Stemline Therapeutics Receives U.S. FDA Approval...

The Menarini Group, a global pharmaceutical company, recently announced that its subsidiary Stemline Therapeutics has received U.S. Food and Drug Administration (FDA) approval for ORSERDU™ (elacestrant) as the first and only treatment for patients with ESR1 mutations in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced...
Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.